Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 6—June 2012

CME ACTIVITY

Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing Enterobacteriaceae and Infection after Liver Transplant, France

Frédéric BertComments to Author , Béatrice Larroque, Catherine Paugam-Burtz, Federica Dondero, François Durand, Estelle Marcon, Jacques Belghiti, Richard Moreau, and Marie-Hélène Nicolas-Chanoine
Author affiliations: Hôpital Beaujon, Clichy, France (F. Bert, B. Larroque, C. Paugam-Burtz, F. Dondero, F. Durand, E. Marcon, J. Belghiti, R. Moreau, M.H. Nicolas-Chanoine); Université Paris VII Faculté de Médecine D. Diderot, Paris, France (C. Paugam-Burtz, F. Durand, J. Belghiti, M.H. Nicolas-Chanoine); INSERM U 773 Centre de Recherche Biomédicale Bichat-Beaujon, CRB3, Paris (F. Durand, R. Moreau, M.H. Nicolas-Chanoine)

Main Article

Table 5

Risk factors for ESBLE infection after liver transplant, by stepwise logistic regression analysis, France, January 2001–April 2010*

Variable† OR (95% CI) p value
Pretransplant ESBLE fecal carriage 18.4 (7.1–47.5) <0.0001
MELD score >25 2.9 (1.4–6.2) 0.0053
Return to surgery 2.7 (1.3–5.9) 0.011

*ESBLE, extended-spectrum β-lactamase-producing Enterobacteriaceae; OR, odds ratio; MELD, Model for End-stage Liver Disease.
†Other factors initially in the model were hepatocellular carcinoma, acute liver failure, pretransplant ICU stay >48h, hospital stay >10 d in the 6 mo before transplant, spontaneous bacterial peritonitis in the 6 mo before transplant, red blood cells transfused, and posttransplant acute renal failure.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO